A novel anti-CD19 chimeric T cell therapy platform ET019002 was safe and effective in inducing CR in blast crisis of CML: A case study.
2019
e18540Background: CML can progress to blast crisis in which the disease behaves like an
acute leukemia. A novel chimeric T-
cell therapyET019002 is built upon Eureka Therapeutics ARTEMIS platform a...
Keywords:
-
Correction
-
Source
-
Cite
-
Save
0
References
0
Citations
NaN
KQI